PROTAC EGFR degrader 15 

PROTAC EGFR degrader 15 is a Pomalidomide (HY-10984)-based Gefitinib (HY-50895) EGFR PROTAC degrader. PROTAC EGFR degrader 15 triggers EGFR degradation via ubiquitin-proteasome-dependent proteolysis and autophagy-lysosome activation pathways. PROTAC EGFR degrader 15 targets ETFA to enhance ATP production. PROTAC EGFR degrader 15 significantly suppresses tumor growth in a Gefitinib-acquired resistant HCC-827 xenograft model. PROTAC EGFR degrader 15 can be used for the study of non-small cell lung cancer (NSCLC) (Pink: EGFR ligand (HY-W109039); Blue: CRBN ligand (HY-10984); Black: Linker (HY-W679737))^[1].

PROTAC EGFR degrader 15 (Compound P-G) (0-1 μM, 24 h + washout 0-72 h) effectively and sustainably induces EGFR protein degradation via both ubiquitin/proteasome pathway and autophagy/lysosome degradation pathway both in HCC-827 parental and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) resistant cells^[1].
PROTAC EGFR degrader 15 (0.5 μM, 44-64°C, 2 h) promotes energy production in HCC-827-ER (Erlotinib (HY-50896) resistance) resistance cells by targeting ETFA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PROTAC EGFR degrader 15 (Compound P-G) (30 mg/kg, i.p., every other day for 2 weeks) effectively suppresses HCC-827-GR xenografts tumors in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

871.40

C₄₅H₅₂ClFN₈O₇

O=C(N1)CCC(N2C(C(C(NC(CCCCCCCCCN3CCN(CCCOC4=CC(C(NC5=CC(Cl)=C(F)C=C5)=NC=N6)=C6C=C4OC)CC3)=O)=CC=C7)=C7C2=O)=O)C1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li L, et al. A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation. Bioorg Chem. 2025 Sep;164:108864.  [Content Brief]